PharmaPoint: Hepatitis C Virus – Brazil Drug Forecast and Market Analysis to 2022
Table Of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 16
3.1.3 Prognosis 17
3.2 Symptoms 17
4 Disease Management 18
4.1 Diagnosis and Referral Overview 18
4.2 Treatment Overview 19
4.3 Brazil 22
4.3.1 Diagnosis 22
4.3.2 Clinical Practice 22
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 23
5.3 Product Profiles - Major Brands 25
5.3.1 Incivek (telaprevir) 25
5.3.2 Victrelis (boceprevir) 30
5.3.3 Pegasys (peginterferon alfa-2a) 34
5.3.4 PegIntron (peginterferon alfa-2b) 38
5.3.5 Copegus, Rebetol, and Generic Ribavirin 42
5.3.6 Therapeutic Class: Interferon 44
6 Opportunity and Unmet Need 45
6.1 Overview 45
6.2 Unmet Needs 46
6.2.1 Unmet Need: Treatment Tolerability 46
6.2.2 Unmet Need: Efficacy 46
6.2.3 Unmet Need: Disease Awareness 47
6.2.4 Unmet Need: Treatment Cost 48
6.2.5 Unmet Need: Shorter Treatment Duration 48
6.2.6 Unmet Need: Simplified Treatment Regimens 49
6.3 Unmet Needs Gap Analysis 49
6.4 Opportunities 50
6.4.1 Opportunity: Pan-genotypic HCV Regimen 50
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 50
6.4.3 Opportunity: Involvement of Immune System 51
7 Pipeline Assessment 52
7.1 Overview 52
7.2 Promising Drugs in Clinical Development 53
7.2.1 Simeprevir 55
7.2.2 Faldaprevir and Faldaprevir plus BI 207127 62
7.2.3 Daclatasvir and Daclatasvir plus Asunaprevir 70
7.2.4 Other Drug Classes 77
8 Market Outlook 81
8.1 Brazil 81
8.1.1 Forecast 81
8.1.2 Key Events 85
8.1.3 Drivers and Barriers 85
9 Appendix 88
9.1 Bibliography 88
9.2 Abbreviations 96
9.3 Methodology 98
9.4 Forecasting Methodology 98
9.4.1 Percent Drug-Treated Patients 98
9.4.2 Patient Warehousing 99
9.4.3 Drugs Included in Each Therapeutic Class 99
9.4.4 General Pricing Assumptions 99
9.4.5 Individual Drug Assumptions 100
9.4.6 Generic Erosion 102
9.4.7 Selection of Pipeline Agents 102
9.4.8 Pricing of Pipeline Agents 103
9.5 Physicians and Specialists Included in this Study 105
9.6 Survey of Prescribing Physicians 107
9.7 About the Authors 108
9.7.1 Author 108
9.7.2 Global Head of Healthcare 108
9.8 About GlobalData 109
9.9 Contact Us 109
9.10 Disclaimer 109
List Of Tables
Table 1: Modes of HCV Transmission 16
Table 2: Symptoms of Acute and Chronic HCV Infection 17
Table 3: HCV Genotypes Present in the 9MM 19
Table 4: General Standard of Care by HCV Genotype 19
Table 5: Treatment Guidelines for HCV by Country 20
Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013 21
Table 7: Leading Treatments for HCV, 2012 24
Table 8: Product Profile - Incivek 26
Table 9: Efficacy of Incivek in Treatment-Naïve Patients (ADVANCE Trial) 26
Table 10: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial) 27
Table 11: Common Incivek Adverse Drug Reactions 28
Table 12: Incivek SWOT Analysis, 2012 29
Table 13: Product Profile - Victrelis 30
Table 14: Victrelis Efficacy in Treatment-Naïve Patients (SPRINT-2 Trial) 31
Table 15: Victrelis Efficacy in Treatment-Experienced Patients (RESPOND-2 Trial) 32
Table 16: Victrelis SWOT Analysis, 2012 34
Table 17: Product Profile - Pegasys 35
Table 18: Antiviral Efficacy of Peginterferon alfa-2a Compared with Interferon alfa-2b 36
Table 19: Pegasys SWOT Analysis, 2012 38
Table 20: Product Profile - PegIntron 39
Table 21: Antiviral Efficacy of Peginterferon alfa-2b Compared with Interferon alfa-2b 40
Table 22: PegIntron SWOT Analysis, 2012 41
Table 23: Effect of Addition of Ribavirin to Peginterferon HCV Therapy 43
Table 24: Ribavirin SWOT Analysis, 2012 44
Table 25: Summary of Minor Therapeutic Classes, 2012 44
Table 26: Overall Unmet Needs - Current Level of Attainment 45
Table 27: Clinical Unmet Needs - Gap Analysis, 2012 49
Table 28: HCV - Pipeline, 2012 53
Table 29: Comparison of Therapeutic Classes in Development for HCV, 2012 55
Table 30: Janssen's Simeprevir Ongoing Clinical Trials of Interest 56
Table 31: Product Profile - Simeprevir 57
Table 32: PILLAR Clinical Trial Results 57
Table 33: Adverse Events Observed in PILLAR Clinical Trial 58
Table 34: Simeprevir SWOT Analysis, 2012 61
Table 35: Boehringer Ingelheim's Faldaprevir Ongoing Clinical Trials of Interest 63
Table 36: Product Profile - Faldaprevir 64
Table 37: Efficacy of Interferon-Free Faldaprevir Regimen (SOUND-C2 Trial) 65
Table 38: Faldaprevir SWOT Analysis, 2012 69
Table 39: Bristol-Myers Squibb's Daclatasvir Ongoing Clinical Trials of Interest 71
Table 40: Product Profile - Daclatasvir 72
Table 41: Efficacy of Daclatasvir in Treatment-Naïve Patients (COMMAND-1 Trial) 72
Table 42: Daclatasvir and Asunaprevir Quad Therapy Efficacy 73
Table 43: Daclatasvir Triple Therapy Adverse Events 74
Table 44: Daclatasvir SWOT Analysis, 2012 77
Table 45: Comparison of Peginterferon lambda with Peginterferon alfa (EMERGE Trial) 78
Table 46: Efficacy of Alisporivir in Treatment-Naïve HCV GT2/3 Patients (VITAL-1 Trial) 79
Table 47: Sales Forecasts ($m) for HCV in Brazil, 2012-2022 83
Table 48: Key Events Impacting Sales for HCV in Brazil, 2012 85
Table 49: Brazilian HCV Market - Drivers and Barriers, 2012 85
Table 50: Physicians Surveyed, By Country 107
List Of Figures
Figure 1: HCV Genome and Polyprotein Composition 13
Figure 2: HCV Lifecycle Overview 14
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012-2022 54
Figure 4: Sales for HCV Therapeutics in Brazil by Drug Class, 2012-2022 84
2015 Market Research Report on Global Diabetes Drugs Industry
Published: 1-Mar-2015 Price: US $2600 Onwards Pages: 166
This is a professional and deep research report in this field.
For overview analysis, the report introduces Diabetes Drugs basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc.
For international and China market analysis, the report analyzes Diabetes Drugs markets in China and other countries or regions (such as US, Europe, Japan, etc) by presenting research on global products of different ......
The Generic Drugs Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts
Published: 18-Feb-2015 Price: US $2500 Onwards Pages: 249
A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights.
Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs.
SNS Research esti......
Global Preventable Vaccines Market 2015-2019
Published: 18-Feb-2015 Price: US $3000 Onwards Pages: 137
Vaccines can be defined as a product that stimulates a person's immune system to produce immunity to a specific disease, thereby protecting the person from that disease. According to the CDC, vaccines are usually administered through needle injections, but can also be administered orally or sprayed into the nose. Vaccines can be used for both adults and infants and adolescents. Pediatric vaccines are used for the immunization of children to give protection against various infectious diseases suc......
2015 Deep Research Report on Global Sodium Chloride Injection Industry
Published: 16-Feb-2015 Price: US $2600 Onwards Pages: 143
This is a professional and deep research report in this field.
For overview analysis, the report introduces Sodium Chloride Injection basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc.
For international and China market analysis, the report analyzes Sodium Chloride Injection markets in China and other countries or regions (such as US, Europe, Japan, etc.) by presenting research on global......
Global Migraine Drugs Market 2015-2019
Published: 4-Feb-2015 Price: US $3000 Onwards Pages: 110
Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines.
TechNavio's analysts forecast the......
EpiCast Report: Atrial Fibrillation – Epidemiology Forecast to 2023
Published: 3-Feb-2015 Price: US $3995 Onwards Pages: 48
Atrial fibrillation (AF) is a disorder of the heart's electrical system. The condition is characterized by an irregular heart rhythm that is either too fast or too slow. During AF, the two upper chambers of the heart (atria) beat out of coordination with the two lower chambers (ventricles) due to disorganized electrical signals, resulting in poor blood supply to the lungs and the rest of the body. The symptoms of AF typically include heart palpitations, irregular and fast heartbeat, chest discom......
2015 Market Research Report on Global Tulobuterol HCl Industry
Published: 3-Feb-2015 Price: US $2600 Onwards Pages: 215
This is a professional and depth research report on Global Tulobuterol HCl industry
For overview analysis, the report introduces Tulobuterol HCl basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc
For international and China market analysis, the report analyzes Tulobuterol HCl markets in China and other countries or regions (such as US, Europe, Japan, etc) by presenting research on global ......
EpiCast Report: Insomnia – Epidemiology Forecast to 2023
Published: 3-Feb-2015 Price: US $3995 Onwards Pages: 67
GlobalData epidemiologists forecast that the total prevalent cases of acute insomnia in the 7MM will increase from 121,799,911 total prevalent cases in 2013, to 130,482,156 total prevalent cases in 2023 at an Annual Growth Rate (AGR) of 0.71%. GlobalData epidemiologists forecast an increase in the total prevalent cases of chronic insomnia (not fulfilling DSM-IV criteria) in the 7MM from 62,982,390 total prevalent cases in 2013, to 67,471,957 total prevalent cases in 2023 at an AGR of 0.71%. The ......
2015 Market Research Report on Global Influenza Vaccine Industry
Published: 1-Feb-2015 Price: US $2600 Onwards Pages: 178
This is a professional and deep research report in this field.
For overview analysis, the report introduces Influenza Vaccine basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc.
For international and China market analysis, the report analyzes Influenza Vaccine markets in China and other countries or regions (such as US, Europe, Japan, etc) by presenting research on global products of diff......
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details - [email protected]
/ +1 888 391 5441 )
- Ad Hoc
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs